Merck ROA 2010-2024 | MRK
Current and historical return on assets (ROA) values for Merck (MRK) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Merck ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2024-03-31 |
$2.31B |
$0.00B |
2.90% |
| 2023-12-31 |
$0.37B |
$106.68B |
0.34% |
| 2023-09-30 |
$4.61B |
$106.73B |
4.31% |
| 2023-06-30 |
$3.11B |
$104.47B |
2.90% |
| 2023-03-31 |
$13.03B |
$107.80B |
12.09% |
| 2022-12-31 |
$14.52B |
$109.16B |
13.51% |
| 2022-09-30 |
$15.26B |
$107.08B |
14.31% |
| 2022-06-30 |
$16.58B |
$107.10B |
16.06% |
| 2022-03-31 |
$14.18B |
$106.67B |
14.30% |
| 2021-12-31 |
$13.05B |
$105.69B |
13.71% |
| 2021-09-30 |
$7.20B |
$93.49B |
7.85% |
| 2021-06-30 |
$5.57B |
$90.69B |
6.14% |
| 2021-03-31 |
$7.03B |
$90.85B |
7.75% |
| 2020-12-31 |
$7.07B |
$91.59B |
7.92% |
| 2020-09-30 |
$11.52B |
$89.80B |
13.17% |
| 2020-06-30 |
$10.48B |
$90.62B |
12.21% |
| 2020-03-31 |
$10.15B |
$84.91B |
12.06% |
| 2019-12-31 |
$9.84B |
$84.40B |
11.79% |
| 2019-09-30 |
$9.31B |
$83.33B |
11.21% |
| 2019-06-30 |
$9.36B |
$83.97B |
11.21% |
| 2019-03-31 |
$8.40B |
$82.35B |
10.02% |
| 2018-12-31 |
$6.22B |
$82.64B |
7.34% |
| 2018-09-30 |
$3.35B |
$85.13B |
3.89% |
| 2018-06-30 |
$1.34B |
$85.04B |
1.53% |
| 2018-03-31 |
$1.58B |
$86.04B |
1.76% |
| 2017-12-31 |
$2.39B |
$87.87B |
2.60% |
| 2017-09-30 |
$2.85B |
$91.68B |
3.03% |
| 2017-06-30 |
$5.09B |
$92.80B |
5.31% |
| 2017-03-31 |
$4.35B |
$96.56B |
4.49% |
| 2016-12-31 |
$3.92B |
$95.38B |
4.03% |
| 2016-09-30 |
$5.49B |
$98.34B |
5.56% |
| 2016-06-30 |
$5.13B |
$96.48B |
5.16% |
| 2016-03-31 |
$4.61B |
$98.76B |
4.57% |
| 2015-12-31 |
$4.44B |
$101.68B |
4.29% |
| 2015-09-30 |
$10.78B |
$101.23B |
10.51% |
| 2015-06-30 |
$9.85B |
$102.58B |
9.59% |
| 2015-03-31 |
$11.17B |
$108.35B |
11.00% |
| 2014-12-31 |
$11.92B |
$98.17B |
11.74% |
| 2014-09-30 |
$5.39B |
$101.81B |
5.21% |
| 2014-06-30 |
$5.61B |
$97.86B |
5.37% |
| 2014-03-31 |
$4.52B |
$108.46B |
4.23% |
| 2013-12-31 |
$4.40B |
$105.65B |
4.14% |
| 2013-09-30 |
$4.53B |
$106.42B |
4.26% |
| 2013-06-30 |
$5.14B |
$106.88B |
4.83% |
| 2013-03-31 |
$6.02B |
$106.20B |
5.68% |
| 2012-12-31 |
$6.17B |
$106.13B |
5.82% |
| 2012-09-30 |
$6.76B |
$106.30B |
6.40% |
| 2012-06-30 |
$6.72B |
$105.53B |
6.36% |
| 2012-03-31 |
$6.95B |
$105.51B |
6.57% |
| 2011-12-31 |
$6.26B |
$105.13B |
5.91% |
| 2011-09-30 |
$4.22B |
$106.53B |
3.98% |
| 2011-06-30 |
$2.87B |
$106.20B |
2.70% |
| 2011-03-31 |
$1.60B |
$105.87B |
1.51% |
| 2010-12-31 |
$0.86B |
$105.78B |
0.80% |
| 2010-09-30 |
$7.84B |
$107.84B |
7.16% |
| 2010-06-30 |
$10.92B |
$106.17B |
11.53% |
| 2010-03-31 |
$11.73B |
$111.59B |
14.56% |
| 2009-12-31 |
$12.85B |
$112.31B |
20.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$332.333B |
$60.115B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
